WALVAX(300142)2025-01-20 10:10Financial Performance - The company expects a net profit attributable to shareholders of approximately RMB 14,000 to 18,000 million for 2024, representing a decline of 57% to 67% compared to the previous year[2]. - The net profit after deducting non-recurring gains and losses is projected to be between RMB 11,000 and 15,000 million, reflecting a decrease of 74% to 81% year-on-year[2]. - The estimated operating revenue for 2024 is around RMB 286,000 million, down from RMB 411,377.23 million in the previous year[2]. - The company anticipates non-recurring gains and losses of about RMB 3,200 million for 2024, compared to -RMB 15,400 million in the previous year[5]. Overseas Business Performance - The company’s overseas business achieved operating revenue of approximately RMB 53,400 million, marking a growth of about 96% compared to the previous year[5]. Research and Development - Research and development expenses decreased by approximately RMB 15,900 million, while R&D investment remains around 20% of operating revenue[5]. - The company has terminated certain R&D projects to focus on core product development while ensuring necessary R&D investments[5]. Market Challenges - The decline in domestic sales revenue is attributed to a decrease in the number of newborns and intensified market competition[4]. Asset Management - The fair value loss from financial assets is estimated at approximately RMB 9,700 million due to stock price declines[5]. - The company conducted impairment testing on assets, resulting in an impairment loss of about RMB 15,900 million[5].